Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells.

BACKGROUND The efficacy and safety of photodynamic therapy for superficial bladder cancer depend on tumor-selective accumulation of the photosensitizer. Bladder transitional-cell carcinoma cells overexpress the transferrin receptor on their surface. We examined whether transferrin-mediated liposomal targeting of the photosensitizer aluminum phthalocyanine tetrasulfonate (AlPcS4) is an effective strategy to attain tumor-selective accumulation of this compound when applied intravesically. METHODS AlPcS4 was stably encapsulated in unconjugated liposomes (Lip-AlPcS4) or transferrin-conjugated liposomes (Tf-Lip-AlPcS4). The accumulation of free AlPcS4, Lip-AlPcS4, and Tf-Lip-AlPcS4 in human AY-27 transitional-cell carcinoma cells and in an orthotopic rat bladder tumor model was visualized by fluorescence microscopy. In vitro AlPcS4 accumulation was quantified by fluorescence measurements following drug extraction, and the photodynamic efficacy of AlPcS4 was measured in a clonogenic assay. All statistical tests were two-sided. RESULTS AY-27 cells incubated with Tf-Lip-AlPcS4 had much higher intracellular AlPcS4 levels than AY-27 cells incubated with Lip-AlPcS4 (384.1 versus 3.7 microM; difference = 380.4 microM, 95% CI = 219.4 to 541.3; P = .0095). Among rats bearing AY-27 cell-derived bladder tumors, intravesical instillation with Tf-Lip-AlPcS4 resulted in mean AlPcS4 fluorescence in tumoral tissue, normal urothelium, and submucosa/muscle of 77.9 fluorescence units (fu) (95% CI = 69.1 to 86.8 fu), 4.3 fu (95% CI = 4.0 to 4.5 fu), and 1.0 (95% CI = 0.1 to 1.9 fu), respectively, whereas instillation of free AlPcS4 resulted in nonselective accumulation throughout the whole bladder wall, and Lip-AlPcS4 instillation resulted in no tissue accumulation. Photodynamic therapy of AY-27 cells incubated with Lip-AlPcS4 resulted in cell viabilities greater than 90% for all concentrations and incubation times tested; photodynamic therapy of cells incubated with 1 muM Tf-Lip-AlPcS4 or AlPcS4 resulted in cell viabilities of 0.19% (95% CI = 0.02% to 0.36%) and 1.32% (95% CI = 0.46% to 2.19%), respectively. Higher concentrations of either AlPcS4 or Tf-Lip-AlPcS4 resulted in cell kills of more than 3 logs. CONCLUSIONS Transferrin-mediated liposomal targeting of photosensitizing drugs is a promising potential tool for photodynamic therapy of superficial bladder tumors.

[1]  T. Allen.  Long-circulating (sterically stabilized) liposomes for targeted drug delivery. , 1994, Trends in pharmacological sciences.

[2]  R. Hurst,et al.  Identification of proteoglycans present at high density on bovine and human bladder luminal surface. , 1994, The Journal of urology.

[3]  D. Wessel,et al.  A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. , 1984, Analytical biochemistry.

[4]  C. Whitehurst,et al.  Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours , 2000, BJU international.

[5]  M. Singh,et al.  Transferrin As A targeting ligand for liposomes and anticancer drugs. , 1999, Current pharmaceutical design.

[6]  M. Walsh,et al.  Transferrin receptor expression by human bladder transitional cell carcinomas , 1987, Urological Research.

[7]  A. Ergen,et al.  Transferrin receptor activity as a marker in transitional cell carcinoma of the bladder. , 1991, British journal of urology.

[8]  C. Beaumont,et al.  Function and regulation of transferrin and ferritin. , 1998, Seminars in hematology.

[9]  D. D. De Vos,et al.  Targeting of the photocytotoxic compound AlPcS4 to hela cells by transferrin conjugated peg‐liposomes , 2002, International journal of cancer.

[10]  T. Wieman,et al.  Complications of whole bladder dihematoporphyrin ether photodynamic therapy. , 1989, The Journal of urology.

[11]  P. Jichlinski,et al.  Photodynamic therapy in superficial bladder cancer: past, present and future , 2001, Urological Research.

[12]  Manyak Mj.  Photodynamic therapy: principles and urologic applications. , 1991 .

[13]  J C Stewart,et al.  Colorimetric determination of phospholipids with ammonium ferrothiocyanate. , 1980, Analytical biochemistry.

[14]  Thomas Filbeck,et al.  Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. , 2002, The Journal of urology.

[15]  D. Golan,et al.  Microtubule inhibitors differentially affect translational movement, cell surface expression, and endocytosis of transferrin receptors in K562 cells , 1994, Journal of cellular physiology.

[16]  Gerald G. Miller,et al.  Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model , 1999, British Journal of Cancer.

[17]  S. W. Moore,et al.  Role of surface mucin in primary antibacterial defense of bladder. , 1977, Urology.

[18]  S. Nishio,et al.  Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma , 1997, Urological Research.

[19]  E. Moase,et al.  Stealth™ Liposomes for the Targeting of Drugs in Cancer Therapy , 1998 .

[20]  G. Gregoriadis.  Targeting of drugs 6 : strategies for stealth therapeutic systems , 1998 .

[21]  Valdir C Colussi,et al.  Photodynamic therapy in oncology , 2001, Expert opinion on pharmacotherapy.

[22]  H. Su,et al.  Expression System for High Levels of GAG Lyase Gene Expression and Study of the hepA Upstream Region in Flavobacterium heparinum , 2002, Journal of bacteriology.

[23]  J Moan,et al.  ACTION SPECTRA OF PHTHALOCYANINES WITH RESPECT TO PHOTOSENSITIZATION OF CELLS , 1992, Photochemistry and photobiology.

[24]  J. Rassweiler,et al.  Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. , 2002, The Journal of urology.

[25]  W. Bezwoda,et al.  Transferrin receptors and transferrin iron uptake by cultured human blood monocytes. , 1987, European journal of cell biology.

[26]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[27]  M. Walsh,et al.  Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences. , 1990, British journal of urology.

[28]  P. D. de Witte,et al.  Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. , 2002, International journal of oncology.

[29]  J. Nickel,et al.  Ultrastructural visualization of human bladder mucous , 2004, Urological Research.

[30]  E. Moase,et al.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.

[31]  T. Hasan,et al.  Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. , 1992, The Journal of urology.

[32]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Wolfhard Semmler,et al.  Macromolecular Contrast Agents for Optical Imaging of Tumors: Comparison of Indotricarbocyanine-labeled Human Serum Albumin and Transferrin¶ , 2000, Photochemistry and photobiology.

[34]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[35]  H. Stuhlsatz,et al.  Quantitative analysis of glycosaminoglycans in urothelium and bladder wall of calf. , 1983, Urology.

[36]  R. Galbraith,et al.  Metabolic and cytoskeletal modulation of transferrin receptor mobility in mitogen-activated human lymphocytes. , 1980, Clinical and experimental immunology.